(+/-)-(4-bromo-2-methoxyphenyl)ethylamine | 138228-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (+/-)-(4-bromo-2-methoxyphenyl)ethylamine
• 英文别名: 1-(4-Bromo-2-methoxyphenyl)ethan-1-amine；1-(4-bromo-2-methoxyphenyl)ethanamine
• CAS: 138228-13-4
• 化学式: C₉H₁₂BrNO
• mdl: MFCD18705432
• 分子量: 230.104
• InChiKey: YNTNFAMPGFYIOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  、 (+/-)-(4-bromo-2-methoxyphenyl)ethylamine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 cis-(+/-)-3-chloro-1,3-dimethyl-N-[1-(4-bromo-2-methoxyphenyl)ethyl]cyclobutanecarboxamide
  参考文献：
  名称：

  Cyclobutane carboxamide inhibitors of fungal melanin: biosynthesis and their evaluation as fungicides

  摘要：

  A new fungicide lead has been identified by enzyme screening of a focused combinatorial library. The lead compound 4, a potent inhibitor of scytalone dehydratase (SD), exhibits fungicidal activity upon foliar application but does not show systemic activity. The X-ray crystal structure of the enzyme-inhibitor complex and an appreciation for the relationship between physical properties and systemic activity enabled us to rapidly improve upon this initial lead. The geminal halogen-methyl group combination was found to be optimal for interaction with the bounding serine and asparagine side-chain residues. Replacement of CF3 with methyl was a key discovery, giving inhibitors with slightly diminished enzyme inhibition potency while significantly increasing systemic activity. Amides prepared from amines with 2,4-dichloro substitution on the phenyl ring gave the most potent enzyme inhibitors. Two compounds from this series showed systemic activity comparable to the commercial standard and were selected for outdoor testing in flooded plots which simulate rice paddies. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00034-1

文献信息

• Compounds with medicinal effects due to interaction with the glucocorticoid receptor
  申请人：Hamilton Morton Niall

  公开号：US20070149577A1

  公开（公告）日：2007-06-28

  The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R 1 is hydrogen, halogen, CN or (1C-4C)alkyl; R 2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R 3 and R 5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R 4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R 6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R 6 is optionally halogenated (1C-4C)alkyl; each R 7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.

  该发明提供了具有以下结构的化合物，符合以下式I的结构：其中：X是碳或氮原子；Ar是苯基或杂环芳香环；R1是氢、卤素、CN或(1C-4C)烷基；R2是氢、卤素或可选氟化的(1C-3C)烷氧基；R3和R5分别是氢、可选卤代的(1C-4C)烷基、可选卤代的(1C-4C)烷氧基、可选卤代的芳基(1C-4C)烷氧基、可选卤代的(1C-4C)烯基或羟甲基；R4是氢、卤素、可选卤代的(1C-4C)烷氧基或可选卤代的芳基(1C-4C)烷氧基；R6是氢、苄基，可选用一个或多个卤素或(1C-4C)烷基取代，或R6是可选卤代的(1C-4C)烷基；每个R7独立地是氢、卤素、可选卤代的(1C-4C)烷基或可选卤代的(1C-4C)烷氧基，以及其药用合适的酸盐，用作糖皮质激素受体调节剂，特别用于治疗中枢神经系统疾病。
• N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0735018A1

  公开（公告）日：1996-10-02

  There is disclosed an N-(α-alkylbenzylidene)-α-phenylalkylamine represented by the general formula (1): wherein R1 represents a lower alkyl group, R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group and X represents a halogen atom or a lower alkoxy group, its use and a process for producing the same and processes for producing intermediates therefor.

  本发明公开了通式(1)代表的N-(α-烷基亚苄基)-α-苯基烷基胺： 其中 R1 代表低级烷基，R2 代表氢原子、卤素原子、低级烷基或低级烷氧基，X 代表卤素原子或低级烷氧基。
• COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR
  申请人：N.V. Organon

  公开号：EP1965785A1

  公开（公告）日：2008-09-10
• US5739401A
  申请人：——

  公开号：US5739401A

  公开（公告）日：1998-04-14
• US6093851A
  申请人：——

  公开号：US6093851A

  公开（公告）日：2000-07-25